Alzheimer's fail crush­es small biotech's share price to near­ly pen­ny stock

Alzheimer’s re­search has wiped out an­oth­er biotech’s mar­ket cap.

Synap­to­genix, a small start­up based out of New York, re­port­ed a Phase II Alzheimer’s fail Fri­day morn­ing, send­ing shares spi­ral­ing near­ly 75%. The study had at­tempt­ed to see whether the drug bryo­statin-1 could im­prove pa­tient scores on a test called the Se­vere Im­pair­ment Bat­tery (SIB) to­tal score as­sess­ment by a sig­nif­i­cant mar­gin af­ter 28 weeks.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER